In the animal trials of INS mutation-induced diabetes, early insulin treatment was shown to protect mice against insulin resistance, α-cell hyperfunction, β-cell loss, and non-β-cell hyperplasia, which seems to give a significantly better prognosis than treating with oral sulfonylureas (19). This evidence concerns the gene INS and diabetes mellitus.